ARWR

Arrowhead Pharmaceuticals, Inc. (ARWR) - 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference (RNAi) therapeutics. The company operates as a single segment and reported a net loss for the period, driven by significant research and development (R&D) investments and commercialization costs for its approved product, REDEMPLO (plozasiran), alongside pipeline expansion.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline (9 Months): Revenue decreased by approximately $160 million compared to the prior year period. This was primarily due to the recognition of the $500 million upfront payment from the Sarepta Collaboration Agreement in the prior year, which is being recognized over time in the current period.
• Expense Increases: R&D expenses increased by $116 million (27%) and SG&A expenses increased by $49 million (56%) year-over-year for the nine-month period. Increases were driven by clinical trial progression, manufacturing scale-up for REDEMPLO, and commercialization launch costs.
• Net Loss: The company reported a net loss of $296.2 million for the nine months ended June 30, 2026, compared to a net income of $22.1 million in the same period of 2025.
• Capital Raises: The company significantly strengthened its balance sheet through a $700 million convertible note issuance, a $230 million follow-on equity offering, and $76 million in ATM offerings during the period.

Guidance, Outlook, and Risks

• Liquidity: Management expects sufficient liquidity to fund operations for at least the next 12 months, supported by $54.8 million in cash and $1.55 billion in marketable securities.
• Commercialization: REDEMPLO has received regulatory approvals in the US, EU, Canada, Australia, and China. The company is actively commercializing the product, leading to increased SG&A costs.
• Pipeline Milestones:
  • Received Breakthrough Therapy designation for plozasiran in severe hypertriglyceridemia.
  • Initiated Phase 1/2a trials for ARO-DIMER-PA (dual-gene targeting) and ARO-MAPT (Alzheimer's).
  • Completed enrollment in the Phase 3 YOSEMITE trial for zodasiran (HoFH).
• Strategic Transactions:
  • Novartis: Received $200 million upfront for CNS programs.
  • Madrigal: Received $25 million upfront for ARO-PNPLA3 (MASH).
  • Sarepta: Received $200 million milestone and $50 million annual fee installment.
• Risks:
  • Patent Litigation: Ionis filed a patent infringement complaint regarding plozasiran; the company intends to vigorously defend.
  • Debt Covenants: The company must maintain liquidity of at least $250 million if market cap exceeds $2 billion.
  • Subsequent Event: Agreed to purchase a Priority Review Voucher (PRV) for $215 million, expected to close in Q4 2026.

Investor Verification Checklist

• Revenue Recognition Timing: Verify the amortization schedule for the Sarepta and Novartis deferred revenue balances ($126 million total) to understand future revenue visibility.
• Debt Structure: Review the terms of the $700 million Convertible Notes (0.00% interest, 2032 maturity) and the $500 million Credit Facility (15% PIK interest, MOIC provisions) to assess dilution risk and cash flow obligations.
• PRV Acquisition: Confirm the closing conditions and funding source for the $215 million Priority Review Voucher purchase announced in July 2026.
• Patent Litigation Status: Monitor the progress of the Ionis patent infringement lawsuit regarding plozasiran.
• Commercialization Costs: Track the trajectory of SG&A expenses as REDEMPLO scales in global markets to ensure alignment with sales growth.